Q-omics provides the consensus-scored OR52B1P profile across patient tissues and cancer cell-line models. OR52B1P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, OR52B1P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, OR52B1P RNA expression shows 6,152 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, LUSC, and STAD as cancer lineages where OR52B1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52B1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52B1P survival associations across molecular data types. OR52B1P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52B1P RNA expression–survival associations across cancer types. High OR52B1P expression shows unfavorable associations in LIHC, CESC, KIRP, COAD, READ and PCPG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for OR52B1P RNA expression.
This table summarizes OR52B1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR52B1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52B1P shows higher tumor expression in LUSC and HNSC. The LUSC box plot shows higher OR52B1P RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .022).
This table shows molecular features associated with OR52B1P in patient tissues and cancer cell lines. In patient samples, OR52B1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52B1P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
